This pharmaceutical company sets the date of registration of the dividend at Rs 150 / share of capital; Know the details

GlaxoSmithKline dividend: GlaxoSmithKline, the mid-cap pharmaceutical company, for the fiscal year 2022, the company has recommended a final dividend and also set the record date for the same. The Company is primarily engaged in the manufacture, trading and distribution of pharmaceutical products and develops a range of products in the fields of pharmaceuticals, vaccines and consumer healthcare.

The company said in an exchange filing against BSE that “the board has recommended a dividend of Rs. 90/- (including a special dividend of Rs. 60) per share on the par value of Rs.10 each for the fiscal year ended March 31, 2022, subject to member approval at the 97th Annual General Meeting to be held on Tuesday, July 26, 2022. In accordance with Regulation 42 of the SEBI Rules (Registration Requirements and Disclosure), 2015, the Company has set Friday July 8, 2022 as the record date for determining the members’ entitlement to the final dividend for the year ended March 31, 2022. The dividend, if approved by the members, will be paid on or after Wednesday July 27, 2022.”

GlaxoSmithKline Shares: Dividend and Share Price History

The company has a good dividend track record and has consistently declared dividends over the past 5 years. For the financial year ended FY21, the company declared a 300% dividend amounting to Rs. 30 per share, and this at the current share price of Rs 1514.90, translates into a dividend of 1.98%.

The stock has fallen 1.91% in the prior year and 13.29% so far in 2022 on a year-to-date basis. Shares of GlaxoSmithKline Pharmaceuticals Ltd have fallen 12.81% over the past six months and 2.34% last month. The stock has fallen 2.47% over the past five trading days. Shares of GlaxoSmithKline Pharmaceuticals Ltd hit a 52-week high of Rs 1,918.75 on December 13, 2021 and a 52-week low of Rs 1,450.00 on October 25, 2021, indicating that the stock is now trading 21% below its 52-week high. and 3.87% above its 52-week low. The stock is trading below the 5-day, 20-day, 50-day, 100-day and 200-day moving averages based on the last traded price.

GlaxoSmithKline Pharmaceuticals reported a consolidated net loss of Rs 55 crore from continuing operations for the March quarter (Q4FY22). The pharmaceutical company had reported a net profit of Rs 4 crore for Q4FY21.

Operating revenue reached 810 crore rupees for the fourth quarter from 744 crore rupees a year ago, the pharmaceutical major said in a regulatory filing.

For the year ended 31 March 2022, the company posted a consolidated net profit from continuing operations of Rs 381 crore, compared to Rs 287 crore in FY21.

In its note dated May 17, ICICI Securities said, “The company’s positioning as a pure domestic formulator and its strong balance sheet with strong brand equity are likely to act as key growth catalysts. While we expect growth in acute therapies to continue over the coming quarters, it would be moderate from last year’s high base. We believe the current valuation already reflects near-term growth potential. We upgrade the stock to HOLD (from Reduce) with a revised target price of Rs1,456/share (before: Rs1,498/share).

The views and investment advice of the experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before making any investment decision.

Read all the latest news, breaking news, watch the best videos and live TV here.

Comments are closed.